Sample collection is named as an intervention in 2 current clinical trials in our France and Italy registers. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Centre Hospitalier Universitaire de Besancon (1). The most-studied condition is Squamous Cell Anal Carcinoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma
NCT04894370 · ClinicalTrials.gov ↗ · Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma
|
Phase 2 | Recruiting | Centre Hospitalier Universitaire de Besancon | France |
|
Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers
NCT07815873 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Melanoma (Skin Cancer), Endometrial Cancer
|
Not applicable | Not yet open | European Institute of Oncology | Italy |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Centre Hospitalier Universitaire de Besancon | 1 |
| European Institute of Oncology | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in France | 1 | 1 |
| Clinical trials in Italy | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our France and Italy registers name Sample collection as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in France. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Centre Hospitalier Universitaire de Besancon (1) and European Institute of Oncology (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Sample collection works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sample collection works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sample collection (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.